SGEN
Seagen Inc. [SGEN] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
SGEN Stock Summary
Top 10 Correlated ETFs
SGEN
Top 10 Correlated Stocks
SGEN
In the News
Signal Says Buy Calls on This Biotech Stock
Biotech stock Seagen Inc (NASDAQ:SGEN) scored an all-time high of $215.04 today, building on a Friday breakout from a consolidation between $204 and $210.
Seagen's (SGEN) Combo Drug Meets Goals in Bladder Cancer Study
Seagen (SGEN) announces positive top-line results from its late-stage study of the Padcev/Keytruda combo in the treatment of adult patients with metastatic bladder cancer. The stock of the company rises 3.5%.
Seagen-Merck Bladder Cancer Treatment Shows Positive Results; Seagen Shares Jump
Biotechnology company Seagen Inc. (SGEN) and Tokyo-based Astellas Pharma Inc. on Friday reported positive results from a Phase 3 trial of their experimental bladder cancer medicine, Padcev, in combination with Merck's (MRK) Keytruda.
Flee to Healthcare Stocks if Recession Rears its Head?
If you're looking for a sector that's on sale, look to healthcare. The Health Care Select Sector SPDR Fund NYSEARCA: XLV is down 2.50% in the past month, lagging the S&P 500.
EU antitrust regulators set Oct. 19 deadline for Pfizer's Seagen deal
Pfizer's $43 billion bid for Seagen will be decided by EU antitrust regulators by Oct. 19, a regulatory filing showed on Friday.
Zai Lab ADR surges after Seagen, Genmab release cervical cancer treatment results
Zai Lab Ltd.'s American depositary receipts ZLAB, +2.47% jumped 14% premarket on Tuesday after Seagen Inc. SGEN, +0.89% and Genmab A/S GMAB, +0.24% announced that Tivdak, their treatment for cervical cancer, improved patients' overall survival in a late-stage study.
Genmab, Seagen say Tivdak cervical cancer trial met overall survival endpoint
Genmab A/S , and Seagen Inc on Monday said that the Phase III trial of Tivdak in recurrent or metastatic cervical cancer patients on or after front-line therapy met its primary endpoint of overall survival.
Seagen's (SGEN) Breast Cancer Study on Tuksya Combo Meets Goal
Seagen (SGEN) announces positive top-line results from its breast cancer study evaluating Tuksya in combination with Roche's Kadcyla.
Seagen's breast cancer therapy meets main goal in late-stage study
Seagen said on Wednesday its breast cancer therapy in combination with Roche's Kadcyla helped extend the time patients lived without their disease progressing in a late-stage trial.
3 Pharmaceutical Stocks to Buy and Hold for the Long Haul
There's a reason why many investors own one or more pharmaceutical stocks. This is a $1.2 trillion industry that is essential to the quality of life for many people.
SGEN Financial details
SGEN Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 4.15 | 5.54 | 12.44 | 8.65 | 10.63 | |
| Net income per share | -1.41 | -0.38 | 3.51 | -3.7 | -3.3 | |
| Operating cash flow per share | -1.29 | -0.99 | 4.9 | -2.74 | -2.46 | |
| Free cash flow per share | -1.43 | -1.42 | 4.43 | -3.03 | -2.88 | |
| Cash per share | 2.6 | 4.9 | 14.64 | 11.87 | 9.4 | |
| Book value per share | 8.08 | 11.34 | 19.95 | 16.84 | 15.18 | |
| Tangible book value per share | 4.44 | 7.86 | 16.76 | 13.9 | 12.41 | |
| Share holders equity per share | 8.08 | 11.34 | 19.95 | 16.84 | 15.18 | |
| Interest debt per share | -0.21 | 0.47 | 0.43 | 0.31 | -0.32 | |
| Market cap | 8.93B | 18.91B | 30.62B | 28.14B | 23.73B | |
| Enterprise value | 8.85B | 18.71B | 30.14B | 27.78B | 23.46B | |
| P/E ratio | -40.11 | -299.01 | 49.9 | -41.73 | -38.89 | |
| Price to sales ratio | 13.64 | 20.63 | 14.07 | 17.88 | 12.09 | |
| POCF ratio | -43.89 | -115.49 | 35.75 | -56.4 | -52.3 | |
| PFCF ratio | -39.74 | -80.64 | 39.55 | -51.05 | -44.69 | |
| P/B Ratio | 7.01 | 10.08 | 8.78 | 9.18 | 8.46 | |
| PTB ratio | 7.01 | 10.08 | 8.78 | 9.18 | 8.46 | |
| EV to sales | 13.52 | 20.41 | 13.85 | 17.64 | 11.95 | |
| Enterprise value over EBITDA | -32.36 | -66.25 | 52.14 | -40.35 | -37.61 | |
| EV to operating cash flow | -43.5 | -114.28 | 35.18 | -55.66 | -51.69 | |
| EV to free cash flow | -39.4 | -79.8 | 38.93 | -50.38 | -44.17 | |
| Earnings yield | -0.02 | 0 | 0.02 | -0.02 | -0.03 | |
| Free cash flow yield | -0.03 | -0.01 | 0.03 | -0.02 | -0.02 | |
| Debt to equity | -0.03 | 0.04 | 0.02 | 0.02 | 0.02 | |
| Debt to assets | -0.02 | 0.03 | 0.02 | 0.02 | 0.01 | |
| Net debt to EBITDA | 0.29 | 0.7 | -0.84 | 0.53 | 0.44 | |
| Current ratio | 2.4 | 3.35 | 6.85 | 3.8 | 2.12 | |
| Interest coverage | 0 | 0 | 0 | 0 | 5.92 | |
| Income quality | 0.91 | 1.03 | 1.4 | 0.74 | 0.74 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0.86 | 0.78 | 0.38 | 0.78 | 0.69 | |
| Intangibles to total assets | 0.38 | 0.26 | 0.14 | 0.14 | 0.14 | |
| Capex to operating cash flow | 0.1 | 0.43 | -0.1 | 0.1 | 0.17 | |
| Capex to revenue | -0.03 | -0.08 | -0.04 | -0.03 | -0.04 | |
| Capex to depreciation | -0.82 | -2.11 | -1.3 | -0.67 | -0.94 | |
| Stock based compensation to revenue | 0.12 | 0.14 | 0.07 | 0.11 | 0.11 | |
| Graham number | 16.03 | 9.87 | 39.69 | 37.46 | 33.6 | |
| ROIC | -0.19 | -0.04 | 0.16 | -0.21 | -0.21 | |
| Return on tangible assets | -0.24 | -0.04 | 0.18 | -0.21 | -0.19 | |
| Graham Net | 2.01 | 4.24 | 13.43 | 10.42 | 7.88 | |
| Working capital | 268.39M | 608.98M | 2.27B | 1.59B | 916.67M | |
| Tangible asset value | 699.23M | 1.3B | 2.93B | 2.53B | 2.29B | |
| Net current asset value | 230.48M | 538.76M | 2.15B | 1.51B | 864.36M | |
| Invested capital | -0.03 | 0.04 | 0.02 | 0.02 | 0.02 | |
| Average receivables | 115.53M | 191.14M | 280.49M | 357.12M | 445.58M | |
| Average payables | 36.77M | 48.24M | 65.18M | 96.45M | 161.34M | |
| Average inventory | 56.61M | 69.59M | 101.03M | 158.4M | 313.94M | |
| Days sales outstanding | 81.55 | 93.97 | 54.52 | 90.24 | 93.35 | |
| Days payables outstanding | 182.63 | 434.26 | 130.88 | 134.52 | 185.01 | |
| Days of inventory on hand | 220.09 | 713.62 | 194.7 | 235.08 | 380.27 | |
| Receivables turnover | 4.48 | 3.88 | 6.69 | 4.04 | 3.91 | |
| Payables turnover | 2 | 0.84 | 2.79 | 2.71 | 1.97 | |
| Inventory turnover | 1.66 | 0.51 | 1.87 | 1.55 | 0.96 | |
| ROE | -0.17 | -0.03 | 0.18 | -0.22 | -0.22 | |
| Capex per share | -0.13 | -0.43 | -0.47 | -0.29 | -0.42 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
| Metric | History | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 2.7 | 2.76 | 2.84 | 2.78 | 3.22 | |
| Net income per share | -0.73 | -1.03 | -0.8 | -0.93 | -1.13 | |
| Operating cash flow per share | -0.39 | -0.46 | -0.43 | -1.34 | -0.93 | |
| Free cash flow per share | -0.47 | -0.55 | -0.58 | -1.54 | -1.2 | |
| Cash per share | 10.05 | 9.54 | 9.32 | 7.97 | 6.89 | |
| Book value per share | 15.93 | 15.27 | 15.07 | 14.57 | 13.96 | |
| Tangible book value per share | 13.08 | 12.47 | 12.31 | 11.86 | 11.29 | |
| Share holders equity per share | 15.93 | 15.27 | 15.07 | 14.57 | 13.96 | |
| Interest debt per share | 0.29 | 0.21 | 0.01 | 0.22 | 0.52 | |
| Market cap | 32.58B | 25.29B | 23.91B | 37.84B | 36.1B | |
| Enterprise value | 32.27B | 24.97B | 23.64B | 37.59B | 35.89B | |
| P/E ratio | -60.42 | -33.13 | -40.35 | -54.14 | -42.66 | |
| Price to sales ratio | 65.49 | 49.55 | 45.28 | 72.81 | 59.78 | |
| POCF ratio | -453.99 | -294.94 | -301.04 | -151.57 | -205.98 | |
| PFCF ratio | -376.53 | -248.71 | -220.04 | -131.25 | -160.81 | |
| P/B Ratio | 11.11 | 8.96 | 8.53 | 13.9 | 13.78 | |
| PTB ratio | 11.11 | 8.96 | 8.53 | 13.9 | 13.78 | |
| EV to sales | 64.86 | 48.93 | 44.76 | 72.34 | 59.43 | |
| Enterprise value over EBITDA | -290.45 | -141.72 | -143.98 | -189 | -154.15 | |
| EV to operating cash flow | -449.6 | -291.26 | -297.56 | -150.59 | -204.78 | |
| EV to free cash flow | -372.89 | -245.61 | -217.49 | -130.4 | -159.87 | |
| Earnings yield | 0 | -0.01 | -0.01 | 0 | -0.01 | |
| Free cash flow yield | 0 | 0 | 0 | -0.01 | -0.01 | |
| Debt to equity | 0.02 | 0.02 | 0.02 | 0.03 | 0.04 | |
| Debt to assets | 0.01 | 0.01 | 0.01 | 0.03 | 0.03 | |
| Net debt to EBITDA | 2.83 | 1.79 | 1.68 | 1.23 | 0.91 | |
| Current ratio | 4.57 | 3.8 | 2.12 | 2.09 | 1.69 | |
| Interest coverage | -41.36 | 22.53 | 3.74 | 3.63 | 0 | |
| Income quality | 0.53 | 0.45 | 0.54 | 1.43 | 0.83 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0.61 | 0.75 | 0.68 | 0.69 | 0.66 | |
| Intangibles to total assets | 0.14 | 0.14 | 0.14 | 0.14 | 0.14 | |
| Capex to operating cash flow | 0.21 | 0.19 | 0.37 | 0.15 | 0.28 | |
| Capex to revenue | -0.03 | -0.03 | -0.06 | -0.07 | -0.08 | |
| Capex to depreciation | -0.72 | -0.76 | -1.41 | -1.75 | -2.28 | |
| Stock based compensation to revenue | 0.11 | 0.12 | 0.12 | 0.12 | 0.15 | |
| Graham number | 16.2 | 18.84 | 16.43 | 17.51 | 18.82 | |
| ROIC | -0.04 | -0.07 | -0.05 | -0.07 | -0.08 | |
| Return on tangible assets | -0.04 | -0.06 | -0.05 | -0.06 | -0.07 | |
| Graham Net | 8.91 | 8.19 | 7.82 | 6.85 | 5.86 | |
| Working capital | 2.17B | 2.03B | 916.67M | 777.04M | 529.22M | |
| Tangible asset value | 2.41B | 2.3B | 2.29B | 2.22B | 2.12B | |
| Net current asset value | 2.08B | 1.96B | 864.36M | 670.13M | 415.8M | |
| Invested capital | 0.02 | 0.02 | 0.02 | 0.03 | 0.04 | |
| Average receivables | 419.53M | 462.4M | 494.33M | 498.84M | 540.91M | |
| Average payables | 108.05M | 136.69M | 176.18M | 174.66M | 127.95M | |
| Average inventory | 297.55M | 342.16M | 396.09M | 452.45M | 482.27M | |
| Days sales outstanding | 79.24 | 85.85 | 85.53 | 85.85 | 87.35 | |
| Days payables outstanding | 109.32 | 120.28 | 172.87 | 113.91 | 56.97 | |
| Days of inventory on hand | 270.89 | 303.8 | 355.32 | 384.63 | 242.41 | |
| Receivables turnover | 1.14 | 1.05 | 1.05 | 1.05 | 1.03 | |
| Payables turnover | 0.82 | 0.75 | 0.52 | 0.79 | 1.58 | |
| Inventory turnover | 0.33 | 0.3 | 0.25 | 0.23 | 0.37 | |
| ROE | -0.05 | -0.07 | -0.05 | -0.06 | -0.08 | |
| Capex per share | -0.08 | -0.09 | -0.16 | -0.21 | -0.26 |
SGEN Frequently Asked Questions
What is Seagen Inc. stock symbol ?
Seagen Inc. is a US stock , located in Bothell of Wa and trading under the symbol SGEN
Is Seagen Inc. buy or a sell ?
13 stock analysts have 13 predictions with a medium analyst target price of $166. The lowest prediction is $120 and the highest is $222
What is SGEN stock prediction ?
What is Seagen Inc. stock quote today ?
Seagen Inc. stock price is $212.24 today.
Is Seagen Inc. stock public?
Yes, Seagen Inc. is a publicly traded company.
Company Profile
- Volume Average 1.17M
- Market Capitalization 40.11B
- Employee 3.26K
- CEO Mr. David R. Epstein B.Sc., M.B.A.
- Headquarters Bothell,WA,US
- IPO Date 2001-03-09
-
Website
https://www.seagen.com 
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
